PF-Atlas › Clinical Trials › NCT02544451

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

LUM/IVA · Phase 3

Registry ID
NCT02544451
Phase
Phase 3
Status
Completed
Drug / intervention
LUM/IVA
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2015-08

About this trial

LUM/IVA is evaluated in NCT02544451, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Vertex Pharmaceuticals Incorporated. Current status: Completed.

View NCT02544451 on ClinicalTrials.gov →

Explore related

All LUM/IVA trialsAll IPF trials

Related trials

LUM/IVA — NCT02875366LUM/IVA — NCT02797132LUM/IVA — NCT03125395LUM/IVA — NCT03061331LUM/IVA — NCT04235140LUM/IVA — NCT03625466
Medical disclaimer. This page summarizes public trial data for NCT02544451 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.